N S Shulman
Affiliation: Stanford University
- Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanismsNancy S Shulman
Department of Medicine, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California 94305, USA
Curr Opin HIV AIDS 2:88-93. 2007..The success of these regimens may partly be a result of the synergistic manner in which the two classes of compounds inhibit the HIV-1 reverse transcriptase enzyme...
- Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patientsAmit Kapoor
Blood Systems Research Institute, San Francisco, CA 94118, USA
Retrovirology 5:7. 2008....
- Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assaysNancy S Shulman
Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA
J Acquir Immune Defic Syndr 39:78-81. 2005..In fact, there was a report that a commercial multicycle assay did not readily detect hypersusceptibility...
- Genotypic correlates of a virologic response to stavudine after zidovudine monotherapyN S Shulman
Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
J Acquir Immune Defic Syndr 27:377-80. 2001..We conclude that in patients with prior ZDV treatment, those with only one ZDV mutation, particularly at position 70, can still get reasonable virologic activity from d4T. Those with more mutations are not likely to have much benefit...
- Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman
Stanford University School of Medicine, California 94305, USA
J Acquir Immune Defic Syndr 31:121-7. 2002..d4T susceptibility greater than 1.4-fold change was associated with failure to achieve significant viral load reduction after 8 weeks of d4T monotherapy...
- Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman
Stanford University School of Medicine, California, USA
Antimicrob Agents Chemother 46:3907-16. 2002..The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response...
- A review of HIV-1 resistance to the nucleoside and nucleotide inhibitorsNancy Shulman
Division of Infectious Diseases, Stanford University, 300 Pasteur Drive, room S 156, Stanford, CA 94305, USA
Curr Drug Targets Infect Disord 3:273-81. 2003....
- Genetic correlates of efavirenz hypersusceptibilityNancy S Shulman
Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
AIDS 18:1781-5. 2004..NNRTI hypersusceptibility has been associated with improved outcomes to NNRTI-based therapy...
- Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic responseN S Shulman
Stanford University School of Medicine, Division of Infectious Diseases, California 94305, USA
J Acquir Immune Defic Syndr 23:221-6. 2000..To determine the impact of prior nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy, genotypic resistance, and other variables on response to efavirenz (EFV)- and adefovir dipivoxil (ADV)-based salvage therapy...
- Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infectionThomas B Campbell
Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
Clin Infect Dis 41:236-42. 2005..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
- Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaquesMark A Winters
AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
Antimicrob Agents Chemother 54:4059-63. 2010..The low concentrations of fetal maraviroc and short pharmacokinetic profile in infants suggest that a single maternal intrapartum dose of maraviroc would not be effective in reducing the risk of MTCT of HIV...
- Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patientsSeverine Margeridon-Thermet
Department of Medicine, Stanford University, Stanford, CA, USA
J Infect Dis 199:1275-85. 2009..UDPS detected low-prevalence HBV variants with NRTI-resistance mutations, G-to-A hypermutation, and low-level dual genotype infection with a sensitivity not previously possible...
- Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitorsShauna A Clark
School of Medicine, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
AIDS 20:981-4. 2006....
- More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175Nancy S Shulman
J Infect Dis 196:328-9; author reply 329-30. 2007
- Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapineDenise Lecossier
INSERM U552, Hopital Bichat Claude Bernard, Paris, France
J Acquir Immune Defic Syndr 38:37-42. 2005..These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens...
- Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistanceJoel E Gallant
The Johns Hopkins University, Baltimore, MD, USA
Antivir Ther 8:489-506. 2003..This review summarizes research advances that further the understanding of nucleoside and nucleotide analogue resistance mutations, and their interplay...
- Non-nucleoside Reverse Transcriptive HypersensitivityNancy Shulman; Fiscal Year: 2006....